Man Group Adds $26M in Alnylam Pharmaceuticals, Inc. ($ALNY)
The fund increased its holdings by 61.1%, reaching 232,369 shares valued at $66.8 million.
Key Points
- Man Group increased its stake in Alnylam Pharmaceuticals by 61.1%, adding 88,159 shares to reach a total of 232,369 shares.
- Alnylam Pharmaceuticals trades on NasdaqGS with a market cap of $38.2 billion and a P/E ratio of 72.0, and its stock price was $287.55 on Wednesday.
- Insider trades included David Pyott buying and selling shares on June 1, 2026, while analysts have set diverse price targets ranging from $330 to $505.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Man Group has significantly increased its investment in Alnylam Pharmaceuticals, Inc. (NasdaqGS: ALNY). According to the latest Form 13F filing with the SEC, the fund boosted its holdings by 61.1%, adding 88,159 shares. This brings its total to 232,369 shares, valued at approximately $66.8 million as of the reporting period.
Man Group vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Man Group's Alnylam Pharmaceuticals Position
Man Group's decision to increase its stake in Alnylam Pharmaceuticals is noteworthy. The fund previously held 144,210 shares and added 88,159 shares, marking a 61.1% increase. The total value of its holdings in Alnylam now stands at about $66.8 million.
Other Institutional Activity in Alnylam Pharmaceuticals
In addition to Man Group's activity, other major funds have also adjusted their positions in Alnylam Pharmaceuticals. FMR LLC reduced its holdings by 1,322,983 shares, ending with 14,579,166 shares worth approximately $4.82 billion, a decrease of 8.3%. Capital World Investors also trimmed its position by 5,499,424 shares, now holding 10,802,348 shares valued at $3.57 billion, reflecting a 33.7% decrease. On the other hand, BlackRock, Inc. increased its stake slightly by 44,034 shares, bringing its total to 10,444,908 shares worth about $3.46 billion, a 0.4% increase. Capital Research Global Investors added 2,691,473 shares, boosting its holdings by 39.7% to 9,471,181 shares valued at $3.13 billion. Vanguard Portfolio Management LLC opened a new position with 6,491,280 shares, valued at approximately $2.15 billion.
Alnylam Pharmaceuticals, Inc. Stock Up 25.7%
Shares of Alnylam Pharmaceuticals traded near $287.55 on Wednesday. The company, which operates in the biotechnology industry, has a market capitalization of $38.2 billion. Its P/E ratio is 72.0, with a forward P/E of 20.8, indicating the company's current earnings relative to its stock price. Alnylam's beta is 0.267, suggesting lower volatility compared to the broader market. The stock has a 52-week low of $273.11 and a high of $495.55. Its 50-day moving average is $300.55, while the 200-day moving average is $374.39. Alnylam maintains a current ratio of 3.13 and a quick ratio of 2.89, with a debt-to-equity ratio of 276.2.
$ALNY stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Alnylam Pharmaceuticals reported revenue of approximately $4.29 billion, with a revenue growth rate of 96.4%. The company's net margin is 12.6%, and it boasts a return on equity of 90.4%. The next earnings report is expected on July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 56.5%. Revenue beat estimates by 2.7%.
-
Profit surprise
EBITDA missed by 5 percent. Operating income beat by 55 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin down 6.1 points. Operating margin up 20.0 points. Negative free cash flow.
Earnings Call Summary
Alnylam delivered 1.17 billion dollars in total product revenue in the first quarter, marking its first quarter exceeding 1 billion dollars. The TTR franchise generated 910 million dollars, up 153 percent year over year, with U.S. revenue growing 230 percent driven by strong AMVUTTRA adoption for heart disease. Management highlighted over 90 percent patient adherence to vutrisiran and broader international success including new launches in Europe and Japan, though Germany pricing adjustments created a temporary headwind that they expect to reverse in coming quarters.
Guidance Management reaffirmed full year guidance of 4.4 to 4.7 billion dollars in TTR revenue, expecting significantly higher quarter-over-quarter growth for the rest of 2026. They also expect the rare disease portfolio to continue contributing steady growth alongside the TTR cardiomyopathy launch expansion in international markets.
Negative report. Results or guidance disappointed and expectations are likely to move lower.
Insider Buying and Selling at Alnylam Pharmaceuticals, Inc.
There has been notable insider activity at Alnylam Pharmaceuticals. On June 1, 2026, David Pyott bought and then sold 3,830 shares under a planned transaction. Benjamin Cravatt acquired 4,393 shares, while Amy Schulman and Olivier Brandicourt bought 838 and 1,441 shares, respectively, on May 20, 2026. These transactions reflect ongoing insider engagement with the company's stock.
Analysts Set New Price Targets
Analyst firms have recently updated their ratings and price targets for Alnylam Pharmaceuticals. On May 19, 2026, Citigroup initiated coverage with a 'buy' rating and a $380 price target. RBC Capital maintained its 'buy' rating with a $445 target on May 1, 2026, while Wells Fargo kept a 'hold' rating with a $377 target. Truist Securities maintained its 'buy' rating with a $505 target on April 13, 2026. The consensus among analysts is a 'buy' recommendation, with an average price target of $436.32 based on 25 analyst opinions.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biotechnology company focused on discovering, developing, and commercializing therapeutics based on RNA interference. The company offers treatments for various conditions, including amyloidosis and hypercholesterolemia, and is working on a robust pipeline of products in different stages of clinical trials. Alnylam collaborates with several major pharmaceutical companies, including Regeneron, Roche, and Sanofi.
Bottom Line
Man Group's decision to significantly increase its stake in Alnylam Pharmaceuticals highlights the fund's confidence in the company's potential. Investors often track such institutional moves for insights into market sentiment. It's important to remember that 13F filings are backward-looking and may not reflect the current position of the fund.
Get Alnylam Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ALNY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.